GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Short Percentage of Float

Aurinia Pharmaceuticals (FRA:IKAP) Short Percentage of Float


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Aurinia Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurinia Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Short Percentage of Float falls into.


;
;

Aurinia Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Short Percentage of Float
Comparable Companies
VRDN INVA SNDX IOVA NVAX ADPT WVE LQDA MDXG ETNB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AUPH:USA
Address
14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Website
https://www.auriniapharma.com
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Headlines

No Headlines